[{"id":"3c5d0961-29c6-44c5-9f18-012dc3b4ae3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06504381","created_at":"2025-02-25T14:04:35.935Z","updated_at":"2025-02-25T14:04:35.935Z","phase":"Phase 1/2","brief_title":"DB107-RRV, DB107-FC, and Radiation Therapy with or Without Temozolomide (TMZ) for High Grade Glioma","source_id_and_acronym":"NCT06504381","lead_sponsor":"University of California, San Francisco","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vocimagene amiretrorepvec/extended release flucytosine (DB107)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/08/2025","start_date":" 01/08/2025","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2042","study_completion_date":" 01/31/2042","last_update_posted":"2025-02-19"}]